Video Experimental Relacionado

Updated: May 2, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Los efectos hipocolesterolemicos del beta-glucano en la harina de avena y el salvado de avena. Un estudio controlado

M H Davidson¹, L D Dugan, J H Burns

¹Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago Center for Clinical Research, IL 60607.

|April 10, 1991

Resumen

Los cereales de avena que contienen fibra de beta-glucano reducen efectivamente los niveles altos de colesterol. El salvado de avena a 56 g mostró la mayor reducción en el colesterol de lipoproteínas de baja densidad (LDL-C), lo que demuestra el efecto reductor del colesterol independiente del beta-glucano.

Área de la Ciencia:

Ciencia de la nutrición Ciencia de la nutrición.
Salud Cardiovascular La salud cardiovascular.
Investigación de la fibra dietética.

Sus antecedentes:

La hipercolesterolemia es un factor de riesgo significativo para las enfermedades cardiovasculares.
La fibra soluble en agua, específicamente el beta-glucano que se encuentra en la avena, se ha investigado por sus propiedades para reducir el colesterol.
Las intervenciones dietéticas son cruciales para manejar los perfiles lipídicos.

Objetivo del estudio:

Para evaluar el efecto hipocolesterolemico de diferentes dosis de cereales de avena (harina de avena y salvado de avena) ricos en beta-glucano.
Para determinar si el salvado de avena o la harina de avena producen mayores reducciones en el colesterol de lipoproteína de baja densidad (LDL-C).
Para establecer una relación dosis-respuesta entre la ingesta de beta-glucano y la reducción del colesterol.

Principales métodos:

Un ensayo controlado aleatorizado en el que participaron 156 adultos con niveles elevados de LDL-C.
Los participantes fueron asignados a siete grupos, que recibieron harina de avena o salvado de avena (28g, 56g, 84g) o un control de harina (28g).
Las muestras de sangre en ayunas se analizaron al inicio y después de 6 semanas de intervención dietética.

Principales resultados:

Se observaron reducciones significativas en el colesterol total y el colesterol LDL en los grupos que consumieron 84 g de harina de avena, 56 g de salvado de avena y 84 g de salvado de avena en comparación con el control de farina.
El grupo de salvado de avena de 56 gramos logró una disminución del 15,9% en el colesterol LDL, que fue significativamente mayor que la reducción del 10,1% observada con avena de 56 gramos.
No se observaron diferencias significativas en el contenido de grasa dietética entre los grupos tratados con avena, destacando el beta-glucano como el componente activo clave.

Conclusiones:

Los cereales de avena, especialmente el salvado de avena, demuestran un efecto hipocolesterolemico dependiente de la dosis, atribuido principalmente a su contenido de beta-glucano.
Las concentraciones más altas de beta-glucano en el salvado de avena contribuyen a reducciones más sustanciales en el colesterol LDL en comparación con la harina de avena en dosis equivalentes.
La ingesta dietética de productos de avena ricos en beta-glucano puede recomendarse como una estrategia efectiva para el manejo de la hipercolesterolemia.

Más Videos Relacionados

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes

Published on: September 9, 2021

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

Videos de Conceptos Relacionados

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...